President Donald Trump’s threat of tariffs on pharmaceutical imports caused biopharma stocks and ETFs to dip after a brief surge. These tariffs would reintroduce costs for businesses that had enjoyed a pause as part of a 104% tariff tussle with China. The largest ETF, iShares Biotechnology ETF, dropped 0.3% in after-hours trading, while the fourth-largest, ARK Genomic Revolution ETF, gained 83% over the same period.
Tariff support for health IT launched in South Korea following Trump’s tariff and more briefs
The South Korean government has launched a tariff support center to assist medical device companies with trade challenges, particularly related to U.S. tariffs. Meanwhile, Johnson
